Aether Industries Limited (NSE: AETHER) and Alivus Life Sciences Ltd (NSE: ALIVUS) are both listed in the Pharmaceutical Contract Manufacturing Services industry. Aether Industries has a market capitalisation of ₹20,196 Cr and Alivus Life Sciences ₹17,772 Cr, as of 9 Nov 2026. Their P/E ratios are 92 and 31.5 respectively. Return on equity is 9.81% for Aether Industries and 18.36% for Alivus Life Sciences. Over one year, Aether Industries's share price is up 108.3% and Alivus Life Sciences's is up 63.1%.
| Metric | Aether Industries | Alivus Life Sciences |
|---|---|---|
| NSE Symbol | AETHER | ALIVUS |
| BSE Code | 543534 | 543322 |
| Share Price | ₹1,586.60 | ₹1,475.00 |
| Market Cap | ₹20,196 Cr | ₹17,772 Cr |
| P/E Ratio | 92 | 31.5 |
| Return on Equity | 9.81% | 18.36% |
| Return on Assets | 6.36% | 12.21% |
| Dividend Yield | — | 0.35% |
| Beta (1Y) | 0.16 | 0.35 |
| 1-Year Price Change | +108.3% | +63.1% |
| 3-Month Price Change | -0.7% | +7.3% |
| 52-Week Range | ₹728.00 – ₹1,814.10 | ₹819.00 – ₹1,554.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹347 Cr | ₹682 Cr |
| Quarterly Net Profit | ₹68 Cr | ₹197 Cr |
| Net Margin | 19.6% | 28.8% |
| EPS (Basic, Quarter) | ₹5.12 | ₹16.02 |
| Results Basis | consolidated | standalone |
| Headquarters | Surat, Gujarat | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Aether Industries Limited produces and sells advanced intermediates and specialty chemicals in India and internationally. It also large-scale manufacturing, contract research and manufacturing services, as well as contract/exclusive manufacturing services. The company serves its products to the chemical industry, including multinational, regional, and domestic companies in the pharmaceuticals, agrochemicals, materials science, textiles, coatings, high-performance photography, additives, and oil and gas industries. It also exports its products. Aether Industries Limited was incorporated in 2013…
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, res…
Aether Industries has a market capitalisation of ₹20,196 Cr, against ₹17,772 Cr for Alivus Life Sciences as of 9 Nov 2026, about 1.1 times the size by market cap.
Aether Industries has a P/E of 92 and Alivus Life Sciences a P/E of 31.5 as of 9 Nov 2026.
Aether Industries has a return on equity of 9.81% and Alivus Life Sciences 18.36%.
Aether Industries's share price is up 108.3% over one year and Alivus Life Sciences's is up 63.1%.
Aether Industries reported revenue of ₹347 Cr and net profit of ₹68 Cr for Q2 FY27. Alivus Life Sciences reported revenue of ₹682 Cr and net profit of ₹197 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Pharmaceutical Contract Manufacturing Services on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.